Corporate Profile for Symbollon Corporation, dated Nov. 27, 1998.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Nov. 27, 1998
Company Name: Symbollon Corporation
Address: 37 Loring Drive
Framingham, Mass. 01702
Main Telephone
Number: 508-620-7676
Chief Financial
Officer: Paul C. Desjourdy
Investor Relations
Contact: Paul C. Desjourdy
Business number: 508-620-7676
Public Relations
Contact: Paul C. Desjourdy
Trading Symbol/
Exchange: SYMBA
Industry: Pharmaceutical Drugs
Company description: Symbollon Corporation is engaged in the development and commercialization of proprietary iodine-based compounds for the prevention and treatment of various human diseases. The company's lead product candidate, IoGen(tm), is currently in Phase II clinical trials Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II for the treatment of fibrocystic breast disease Noun 1. fibrocystic breast disease - the presence of one or more cysts in a breast cystic breast disease, cystic mastitis, fibrocystic disease of the breast disease - an impairment of health or a condition of abnormal functioning . Fibrocystic breast disease is a benign breast condition affecting approximately 30% of the women of child-bearing age, which represents in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. about 24 million women. Publications covering previous independent third party testing utilizing iodine iodine (ī`ədīn, –dĭn) [Gr.,=violet], nonmetallic chemical element; symbol I; at. no. 53; at. wt. 126.9045; m.p. 113.5°C;; b.p. 184.35°C;; sp. gr. 4.93 at 20°C;; valence −1, +1, +3, +5, or +7. to treat collectively over 1,500 women with fibrocystic breast disease have reported 60% or greater clinical improvement in their breast disease. The company is also collaborating with Bausch & Lomb Pharmaceuticals and Watson Pharmaceuticals Watson Pharmaceuticals, Incorporated (NYSE: WPI) is the 5th largest pharmaceutical company in the United States based on number of prescriptions dispensed. Based in Corona, California, Watson's Generics division markets over 150 pharmaceutical product families, including one of the to develop drug compounds based on the company's technology. With Bausch & Lomb, the company is developing new drugs for treating ophthalmic ophthalmic /oph·thal·mic/ (of-thal´mik) ocular (1). oph·thal·mic adj. Of or relating to the eye; ocular. Ophthalmic Pertaining to the eye. infections. The company is working with Watson to develop applications to treat human skin diseases. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion